Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

HER2 testing in patients with breast cancer.

Dixon JM, Wilson V, Verrill M, Symmans WF.

BMJ. 2012 Jun 11;344:e3958. doi: 10.1136/bmj.e3958. No abstract available.

PMID:
22689887
2.

HER2-directed therapy: current treatment options for HER2-positive breast cancer.

Ahmed S, Sami A, Xiang J.

Breast Cancer. 2015 Mar;22(2):101-16. doi: 10.1007/s12282-015-0587-x. Epub 2015 Jan 30. Review.

PMID:
25634227
3.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

PMID:
22649126
4.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
5.

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Khasraw M, Bell R.

Expert Rev Anticancer Ther. 2012 Aug;12(8):1005-13. doi: 10.1586/era.12.62. Review.

PMID:
23030220
6.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

PMID:
23827380
7.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4.

PMID:
24095300
8.

The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.

Abair T, O'Shaughnessy J.

Clin Breast Cancer. 2011 Feb;11(1):15-9. doi: 10.3816/CBC.2011.n.003. No abstract available.

PMID:
21989832
9.

HER2-positive metastatic breast cancer: a changing scenario.

Mustacchi G, Biganzoli L, Pronzato P, Montemurro F, Dambrosio M, Minelli M, Molteni L, Scaltriti L.

Crit Rev Oncol Hematol. 2015 Jul;95(1):78-87. doi: 10.1016/j.critrevonc.2015.02.002. Epub 2015 Feb 20. Review.

PMID:
25748080
10.

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.

Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M.

Oncotarget. 2014 Oct 30;5(20):9619-25.

11.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P.

Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.

PMID:
22153890
12.

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.

Corrigan PA, Cicci TA, Auten JJ, Lowe DK.

Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Review.

PMID:
25082874
14.

[HER2-positive breast cancer: standard and double targeted therapy].

Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS.

Vopr Onkol. 2013;59(3):341-6. Russian.

PMID:
23909035
15.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP; American Society of Clinical Oncology.

J Clin Oncol. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5. Review.

PMID:
24799465
16.

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Yardley DA, Krop IE, LoRusso PM, Mayer M, Barnett B, Yoo B, Perez EA.

Cancer J. 2015 Sep-Oct;21(5):357-64. doi: 10.1097/PPO.0000000000000144.

PMID:
26389758
17.

Medicine: Eyes on the target.

Eisenstein M.

Nature. 2015 Nov 19;527(7578):S110-2. doi: 10.1038/527S110a. No abstract available.

PMID:
26580159
18.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.

Lancet Oncol. 2014 Dec;15(13):1493-502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30.

PMID:
25456368
19.

Trastuzumab-containing regimens for metastatic breast cancer.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R.

Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242. doi: 10.1002/14651858.CD006242.pub2. Review.

20.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.

J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.

PMID:
20308670

Supplemental Content

Support Center